Concurrent progress of reprogramming and gene correction to overcome therapeutic limitation of mutant ALK2-iPSC

Cited 33 time in scopus
Metadata Downloads

Full metadata record

DC FieldValueLanguage
dc.contributor.authorB Y KIm-
dc.contributor.authorS Jeong-
dc.contributor.authorS Y Lee-
dc.contributor.authorS M Lee-
dc.contributor.authorE J Gweon-
dc.contributor.authorHyunjun Ahn-
dc.contributor.authorJanghwan Kim-
dc.contributor.authorS K Chung-
dc.date.accessioned2017-04-19T10:22:57Z-
dc.date.available2017-04-19T10:22:57Z-
dc.date.issued2016-
dc.identifier.issnI000-0028-
dc.identifier.uri10.1038/emm.2016.35ko
dc.identifier.urihttps://oak.kribb.re.kr/handle/201005/13296-
dc.description.abstractFibrodysplasia ossificans progressiva (FOP) syndrome is caused by mutation of the gene ACVR1, encoding a constitutive active bone morphogenetic protein type I receptor (also called ALK2) to induce heterotopic ossification in the patient. To genetically correct it, we attempted to generate the mutant ALK2-iPSCs (mALK2-iPSCs) from FOP-human dermal fibroblasts. However, the mALK2 leads to inhibitory pluripotency maintenance, or impaired clonogenic potential after single-cell dissociation as an inevitable step, which applies gene-correction tools to induced pluripotent stem cells (iPSCs). Thus, current iPSC-based gene therapy approach reveals a limitation that is not readily applicable to iPSCs with ALK2 mutation. Here we developed a simplified one-step procedure by simultaneously introducing reprogramming and gene-editing components into human fibroblasts derived from patient with FOP syndrome, and genetically treated it. The mixtures of reprogramming and gene-editing components are composed of reprogramming episomal vectors, CRISPR/Cas9-expressing vectors and single-stranded oligodeoxynucleotide harboring normal base to correct ALK2 c.617G>A. The one-step-mediated ALK2 gene-corrected iPSCs restored global gene expression pattern, as well as mineralization to the extent of normal iPSCs. This procedure not only helps save time, labor and costs but also opens up a new paradigm that is beyond the current application of gene-editing methodologies, which is hampered by inhibitory pluripotency-maintenance requirements, or vulnerability of single-cell-dissociated iPSCs.-
dc.publisherSpringer-Nature Pub Group-
dc.titleConcurrent progress of reprogramming and gene correction to overcome therapeutic limitation of mutant ALK2-iPSC-
dc.title.alternativeConcurrent progress of reprogramming and gene correction to overcome therapeutic limitation of mutant ALK2-iPSC-
dc.typeArticle-
dc.citation.titleExperimental and Molecular Medicine-
dc.citation.number6-
dc.citation.endPagee237-
dc.citation.startPagee237-
dc.citation.volume48-
dc.contributor.affiliatedAuthorHyunjun Ahn-
dc.contributor.affiliatedAuthorJanghwan Kim-
dc.contributor.alternativeName김부여-
dc.contributor.alternativeName정상균-
dc.contributor.alternativeName이세영-
dc.contributor.alternativeName이소민-
dc.contributor.alternativeName권은정-
dc.contributor.alternativeName안현준-
dc.contributor.alternativeName김장환-
dc.contributor.alternativeName정선구-
dc.identifier.bibliographicCitationExperimental and Molecular Medicine, vol. 48, no. 6, pp. e237-e237-
dc.identifier.doi10.1038/emm.2016.35-
dc.description.journalClassY-
Appears in Collections:
Division of Research on National Challenges > Stem Cell Convergenece Research Center > 1. Journal Articles
Files in This Item:
  • There are no files associated with this item.


Items in OpenAccess@KRIBB are protected by copyright, with all rights reserved, unless otherwise indicated.